Bayesian Capital Management, LP Fate Therapeutics Inc Transaction History

Bayesian Capital Management, LP

  • $838 Million
  • Q3 2024

A detailed history of Bayesian Capital Management, LP transactions in Fate Therapeutics Inc stock. As of the latest transaction made, Bayesian Capital Management, LP holds 17,174 shares of FATE stock, worth $28,508. This represents 0.01% of its overall portfolio holdings.

Number of Shares
17,174
Holding current value
$28,508
% of portfolio
0.01%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024
BUY
$3.12 - $5.57 $53,582 - $95,659
17,174 New
17,174 $60,000
Q1 2024

May 15, 2024
BUY
$3.54 - $8.35 $71,380 - $168,369
20,164 Added 102.69%
39,800 $292,000
Q4 2023

Feb 14, 2024
SELL
$1.65 - $3.94 $30,690 - $73,284
-18,600 Reduced 48.65%
19,636 $73,000
Q3 2023

Nov 14, 2023
SELL
$2.02 - $5.04 $44,440 - $110,880
-22,000 Reduced 36.52%
38,236 $81,000
Q2 2023

Aug 14, 2023
BUY
$4.76 - $6.59 $151,844 - $210,221
31,900 Added 112.58%
60,236 $286,000
Q1 2023

May 15, 2023
BUY
$4.24 - $11.12 $40,704 - $106,751
9,600 Added 51.24%
28,336 $161,000
Q4 2022

Feb 14, 2023
BUY
$9.86 - $23.83 $38,454 - $92,937
3,900 Added 26.29%
18,736 $189,000
Q3 2022

Nov 14, 2022
BUY
$21.04 - $36.06 $312,149 - $534,986
14,836 New
14,836 $332,000
Q2 2021

Aug 13, 2021
SELL
$67.25 - $92.52 $423,675 - $582,876
-6,300 Closed
0 $0
Q1 2021

May 14, 2021
BUY
$72.16 - $117.4 $454,608 - $739,620
6,300 New
6,300 $519,000

Others Institutions Holding FATE

# of Institutions
175
Shares Held
115M
Call Options Held
53.7K
Put Options Held
9K
View Full List

About FATE THERAPEUTICS INC

FATE Quotes by TradingView
  • Ticker FATE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 97,000,304
  • Market Cap $161M
  • Description
  • Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...
More about FATE
Track This Portfolio

Track Bayesian Capital Management, LP Portfolio

Follow Bayesian Capital Management, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bayesian Capital Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Bayesian Capital Management, LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email